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Abstract 26 
Background: Bilirubin has potential antioxidant and anti-inflammatory properties. The 27 
UGT1A1*28 polymorphism (TA duplication in the TATA box region of the UGT1A1 gene 28 
promoter) is a major determinant of bilirubin levels and recent evidence suggest that raised 29 
adiposity may also be a contributing factor.  30 
Objective: To study the interaction between UGT1A1*28 polymorphism and both 31 
haematological and anthropometric variables on total bilirubin levels in young individuals. 32 
Methods: We studied 350 obese (mean age of 11.6 years; 52% females) and 79 controls 33 
(mean age of 10.5 years; 59% females). Anthropometric data, UGT1A1*28 polymorphism, 34 
haemogram and plasma levels of total bilirubin, C-reactive protein (CRP), glucose and insulin 35 
were evaluated. In a subgroup of 74 obese and 40 controls body composition was analyzed by 36 
dual-energy X-ray absorptiometry.   37 
Results: The UGT1A1 genotype frequencies in all studied individuals were 49.9%, 42.7% 38 
and 7.5% for 6/6, 6/7 and 7/7 genotypes, respectively. Patients with 7/7 genotype presented 39 
the highest total bilirubin levels, followed by 6/7 and 6/6 genotypes. Compared to controls, 40 
obese patients presented higher erythrocyte count, haematocrit values and haemoglobin, 41 
insulin and CRP levels, but no differences in bilirubin or in UGT1A1 genotype distribution. 42 
Body fat percentage was negatively correlated with bilirubin in obese patients but not in 43 
controls. This negative association was observed either in 6/7 or 6/6 genotype obese patients. 44 
The UGT1A1*28 polymorphism and body fat percentage were the main factors affecting 45 
bilirubin levels within obese patients, by linear regression analysis (standardised Beta: 0.348, 46 
-0.291; p = 0.002 and p = 0.009, respectively).  47 
Conclusions: In obese children and adolescents, body fat composition and UGT1A1*28 48 
polymorphism are independent determinants of total bilirubin levels. Raised inflammation 49 
and oxidative stress in obese patients may trigger the consumption of bilirubin. 50 
51 
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Introduction 52 
Bilirubin is the ultimate product of the haem group catabolism and serves as a diagnostic 53 
marker of liver and blood disorders [1]. Bilirubin is a water-insoluble compound that 54 
circulates bounded to albumin and requires glucuronidation by a microsomal enzyme, the 55 
uridine diphosphate glucuronosyltransferase (UGT) 1A1, to be excreted. The UGT1A1 gene 56 
locus has been mapped to chromosome 2q37 [2] and one of the most common genetic 57 
variants that affects the glucuronidation of bilirubin is a TA duplication polymorphism in the 58 
TATA box region of the gene promoter. Homozygous individuals carrying the A(TA)7TAA 59 
allele have higher levels of unconjugated bilirubin (UCB), caused by a reduction of 30% in 60 
the UGT1A1 transcription [3]. The estimated frequency of this allele is 0.35 in Caucasians, 61 
leading to a homozygous genotype in about 10% of the population, but the frequency is 62 
highly variable in different ethnicities [4, 5]. Homozygosis for the TA duplication was 63 
considered as the main cause of Gilbert syndrome in Caucasian population [3, 4], and justify 64 
some of the inter-individual variations in bilirubin levels [6]. 65 
Under certain conditions bilirubin can be toxic [7]. High plasma concentrations are 66 
associated with deleterious effects in new-borns, increasing the risk of neurological 67 
dysfunction [7, 8], as a result of its toxic effect on neuronal tissue. However, recent 68 
investigation has recognized that UCB exerts anti-oxidant and anti-inflammatory activities, 69 
and that mild hyperbilirubinaemia might have positive health effects. UCB inhibits lipid 70 
peroxidation [9] and suppresses inflammation in activated neonatal neutrophils [10], and 71 
population studies documented that individuals with higher circulating UCB have a reduced 72 
incidence of cardiovascular problems [11-13] and of carcinoma in general [14]. Furthermore, 73 
subjects with Gilbert syndrome seem to present low levels of oxidative stress associated with 74 
hyperbilirubinaemia [15]. 75 
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Obesity, a low-grade inflammatory disease [16], is increasing all over the world and is a 76 
significant risk factor for cardiovascular disease (CVD). This is of particular concern in our 77 
country, considering the very high prevalence of overweight/obesity (31.5%) in Portuguese 78 
children when compared to other European countries [17]. In obesity, cardiovascular 79 
morbidity and mortality are associated with classic risk factors, namely dyslipidaemia, 80 
hypertension and impaired glucose metabolism. These risk factors, known as predictive of 81 
CVD, are characteristic of the metabolic syndrome (MS) [18]. Moreover, serum bilirubin 82 
levels are inversely associated with the MS and systemic inflammation in adults [19-21], as 83 
well as in children and adolescents [22]. In particular, abdominal obesity per se seems to be 84 
associated with low serum bilirubin levels [21-23]. Furthermore, a recent study hypothesized 85 
that circulating bilirubin levels might be already altered in overweight asymptomatic middle-86 
aged individuals before full development of the MS [24]. 87 
The aim of our work was to evaluate how total bilirubin (TB) levels are influenced by 88 
UGT1A1*28 polymorphism, haematological, biochemical and anthropometric variables in 89 
Portuguese obese children and adolescents.  90 
 91 
Material and methods 92 
 93 
Study population 94 
Obese children and adolescents, aged 4-18 years, were identified from medical records, at 95 
the outpatient clinics of pediatric obesity in two hospitals in Porto - Portugal. A group of 96 
children from 5 primary and 2 middle and high public schools from Oporto suburban setting, 97 
were also recruited to this study, providing a control group and enlarging the obese group.  98 
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Smokers, subjects with diabetes mellitus, endocrine disorders, hereditary diseases, 99 
inflammatory or infectious diseases or under any therapy that could interfere with our results 100 
were excluded from the study. 101 
 102 
Ethics approval and patient consent 103 
The study protocol was approved by the Committee on Ethics of Oporto Hospital Centre, 104 
the Committee on Ethics of Hospital São João, the Review Committee of the Scientific Board 105 
of the Faculty of Sport of the University of Porto as well as by the Foundation of Science and 106 
Technology. 107 
A total of 350 obese children and adolescents and 79 controls participated in the study after 108 
informed and written consent of their parents.  109 
 110 
Anthropometric characterization and clinical evaluation 111 
All participants were subjected to clinical examination. Height and weight were measured. 112 
Obesity was defined as body mass index (BMI) z-score greater than +1.65 for age and gender, 113 
according to 2000 Centre for Disease Control and Prevention (CDC) growth charts. Body 114 
composition was evaluated by dual-energy X-ray absorptiometry (DEXA) in a subgroup of 115 
participants (74 obese and 40 controls).  116 
 117 
Blood samples 118 
Blood was collected by venipuncture in EDTA containing tubes, after overnight fasting 119 
(10-12h) and processed within 2h of collection. Aliquots of buffy-coat and plasma were 120 
made, and immediately stored at -80oC until assayed. 121 
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Haematological data 122 
Red blood cell (RBC) count, haematocrit (Ht), haemoglobin (Hb) concentration and 123 
haematimetric indices [mean cell volume (MCV), mean cell Hb (MCH) and mean cell Hb 124 
concentration (MCHC)] were measured by using an automatic blood cell counter (ABX 125 
Micros 60-OT).  126 
 127 
DNA analysis 128 
Genomic DNA was extracted from buffy-coat by proteinase K/salt precipitation method 129 
[25, 26]. Genotyping TA duplication in the TATA box of the UGT1A1 promoter was 130 
performed by polymerase chain reaction (PCR) (forward: 5´-131 
TAACTTGGTGTATCGATTGGTTTTTG-3´; reverse: 5´-ACAGCCATGGCGCCTTTGCT-132 
3´). PCR was followed by electrophoresis in 15% polyacrylamide gel in a Tris/Borate/EDTA 133 
buffer. The gel was stained with silver nitrate, photographed and samples were classified. 134 
 135 
Plasma analysis 136 
The plasma levels of C-reactive protein (CRP) were determined by immunoturbidimetry 137 
[CRP (latex) High-Sensitivity, Roche Diagnostics] and quantification of TB was performed 138 
by a colorimetric test (diazotized sulfanilic acid reaction, Roche Diagnostics). 139 
The determination of circulating levels of glucose and insulin was performed by using 140 
routine automated technology (ABX Diagnostics). Homeostasis model assessment of insulin 141 
resistance (HOMAIR) was calculated [27]. 142 
 143 
Statistical analysis 144 
The distributions of continuous variables were analysed using Kolmogorov-Smirnov 145 
tests. Normally distributed variables are presented as mean ± SD and those non-normally 146 
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distributed are presented as median (interquartile range). Comparisons between two groups 147 
were performed using Student’s unpaired t-test or Mann-Whitney U test. Adjustment for 148 
confounding factors was performed using ANCOVA. The association between categorical 149 
variables was analysed using chi-squared (χ2) test and Fisher’s exact test. 150 
The strength of the association between the variables was estimated by Pearson 151 
correlation coefficient, after log transformation of the variables (whenever necessary). To 152 
evaluate the contribution of the different variables to TB levels, multiple regression analysis 153 
was performed, using stepwise selection, with an entry criteria of p <0.05.  154 
Statistical analysis was performed using the Statistical Package for Social Sciences 155 
(SPSS), version 20.0 (IBM, Armonk, NY, USA). Statistical significance was accepted at p 156 
less than 0.05. 157 
 158 
Results 159 
The anthropometric data, UGT1A1 genotypes, haematological and biochemical parameters 160 
of the obese children and adolescents (n=350) and controls (n=79), according to gender, are 161 
presented in Table 1.  162 
Comparing males and females within the control group, body fat and trunk fat percentages 163 
were significantly lower for boys, whereas RBC count, Hb levels and MCHC values were 164 
significantly higher. Within obese patients, RBC count, Hb levels and Ht values were 165 
significantly higher for boys, whereas insulin levels and HOMAIR values were lower. No 166 
statistical significant differences were found in the distribution of subjects with respect to 167 
UGT1A1 genotypes or in TB levels between boys and girls, within both groups.  168 
Compared to controls (independently of gender), obese patients presented significantly 169 
higher height, weight, BMI, BMI z-score, body fat and trunk fat percentages, erythrocyte 170 
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count, Ht and HOMAIR values and Hb, insulin and CRP levels, but no significant differences 171 
in TB levels or in UGT1A1 genotype distribution.  172 
The UGT1A1 genotype frequencies in all studied individuals were 49.9%, 42.7% and 7.5% 173 
for 6/6, 6/7 and 7/7 genotypes, respectively. UGT1A1*28 polymorphism was associated with 174 
different TB levels (Fig. 1A); patients with 7/7 genotype presented the highest TB levels, 175 
followed by 6/7 and 6/6 genotypes (p<0.01 between all groups). No significant differences 176 
were observed between obese and control individuals, for the different UGT1A1 genotypes 177 
(Fig. 1B). 178 
Within the control group (n=79), TB levels correlated positively and significantly with age 179 
(r=0.304, p=0.007), height (r=0.360, p=0.001), weight (r=0.390, p<0.001), BMI (r=0.370, 180 
p=0.001), Ht (r=0.247, p=0.028), MCV (r=0.292, p=0.009), and correlated negatively and 181 
significantly with MCHC (r=-0.258, p=0.022). Within the obese group (n=350), TB levels 182 
correlated positively and significantly with age (r=0.284, p<0.001), height (r=0.285, 183 
p<0.001), weight (r=0.219, p<0.001), BMI (r=0.123, p=0.021), Hb (r=0.305, p<0.001), Ht 184 
(r=0.352, p<0.001), MCV (r=0.394, p<0.001), MCH (r=0.301, p<0.001) and correlated 185 
negatively and significantly with BMI z-score (r=-0.131, p=0.014), MCHC (r=-0.149, 186 
p=0.006) and CRP (r =-0.178, p=0.001). 187 
The characteristics of obese patients that evaluated their body composition by DEXA 188 
(n=74) are presented in Table 2. These obese patients were divided in two groups according 189 
on having a body fat lower or higher/equal than 42.5% (cut-off that corresponds to the median 190 
value for the obese group). The two groups of obese patients were matched for gender and 191 
UGT1A1 genotype distribution, but not for age. Patients presenting higher body fat had lower 192 
bilirubin and higher CRP levels (Table 2). These differences were similar to both sexes (Fig. 193 
2) and remained statistically significant after adjustment for age. No significant differences in 194 
HOMAIR values were found between the two groups.  195 
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Associations between body and trunk fat were only accessed in participants that evaluated 196 
their body composition by DEXA (74 obese and 40 controls). Body fat and trunk fat 197 
percentages were negatively and significantly related with TB levels in obese patients (r =-198 
0.287, p=0.013 and r=-0.245, p=0.038) but not within controls (r=0.012, p=0.941 and 199 
r=0.014, p=0.002).  200 
By linear regression analysis, the UGT1A1*28 polymorphism and body weight were the 201 
only factors associated to bilirubin levels within controls (Ln TB= 1.143 + 0.462 UGT1A1*28 202 
polymorphism + 0.014 weight; standardised Beta: 0.598 and 0.490; p<0.001 and p=0.001, 203 
respectively). Within obese patients, the UGT1A1 polymorphism and body fat percentage 204 
were the main determinant factors of bilirubin levels (Ln TB= 2.761 + 0.251 UGT1A1*28 205 
polymorphism -0.020 body fat; standardised Beta: 0.348, -0.291; p=0.002 and p=0.009, 206 
respectively). For a better visualization of the results (graphically), obese participants were 207 
divided on the basis of their UGT1A1 genotype and on having a body fat lower or 208 
higher/equal than 42.5% (cut-off that corresponds to the median value for the obese group; 209 
Fig. 3). 210 
 211 
Discussion 212 
As far as we know, this is the first report assessing the concomitant influence of 213 
UGT1A1*28 polymorphism and adiposity markers on bilirubin levels in obese children and 214 
adolescents. We demonstrated that body fat percentage is a major determinant of TB levels 215 
independently of UGT1A1*28 polymorphism in obese children and adolescents. 216 
It is known that UGT1A1 polymorphisms are associated with bilirubin levels and our data 217 
is in agreement with previous reports in young patients and adults [15, 28-30]. Patients and 218 
controls with 7/7 genotype presented the highest TB levels, followed by 6/7 and 6/6 219 
genotypes (Fig. 1A and 1B).  220 
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The frequency of 7/7 homozygotes (7.5% in the whole population) was lower than that 221 
observed in other works, namely in healthy Greek [29] and Slovenian [30] populations, with 222 
frequencies of 14.8% and 13.6%, respectively. However, the distribution of subjects with 223 
respect to UGT1A1 genotypes was similar to that found in previous studies involving 224 
Portuguese children with Hereditary spherocytosis, with a 7/7 frequency of 8.8% [28], as well 225 
as Portuguese healthy subjects, with frequencies observed in two studies of 6.3 and 9.9% [28, 226 
31]. Thus, it seems reasonable to assume that the frequency of 7/7 homozygotes in the 227 
Portuguese population may be lower than that observed in other Caucasian populations.  228 
Other potential variables could influence TB levels. Within both controls and obese 229 
patients TB levels were positively and significantly correlated with age, height, weight, BMI, 230 
and Ht. However, BMI z-score, body fat and trunk fat percentages were negatively and 231 
significantly related with TB levels in obese patients, but not within controls. In multiple 232 
regression analysis, the UGT1A1*28 polymorphism and body weight were the only factors 233 
associated to bilirubin levels within controls, whereas the UGT1A1*28 polymorphism and 234 
body fat percentage were the main determinant factors of bilirubin levels within obese 235 
patients.  236 
In the present study, the evaluation of body composition by DEXA was performed in a 237 
subgroup of participants. Despite the lower number of participants in this sub-analysis, the 238 
negative relation between bilirubin and body fat percentage was highly statistically significant 239 
and independent of the effect of UGT1A1*28 polymorphism. Furthermore, this negative 240 
relation is in agreement with a previous study involving 41 lean and obese adult men and 241 
women [23]. 242 
Bilirubin derives mainly from the haem present in Hb, released during breakdown of 243 
senescent erythrocytes [1]. Thus, in healthy conditions, it would be assumed that increases in 244 
Hb levels are generally associated with increases in TB. This explains our positive association 245 
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between the age of the participants and TB, as in young individuals there is a physiological 246 
increase in Hb levels with age.  It is well known that Hb and Ht increase substantially during 247 
childhood, whereas RBC count remains almost constant [32]. Differences according to gender 248 
become prominent in the second decade of life; with menstruation, these three variables tend 249 
to be lower in females.  The inclusion in our study of subjects with a range of age between 4 250 
and 18 years old justifies the higher values of RBC and Hb observed in males within both 251 
controls and obese patients (Table 1). The differences were particularly evident in obese 252 
patients, not only because of the large number of subjects included in this group but also due 253 
to the enhanced puberty development in obesity. Actually, the increasing prevalence of 254 
obesity in children worldwide is a major cause of precocious pubertal maturation, verified 255 
during the past decades [33]. 256 
Total and direct bilirubin levels were reported to be higher in normal weight adult males 257 
than in females [24, 34, 35], but similar within overweight patients [24]. In our study, we 258 
observed no statistical significant differences between boys and girls regarding TB levels, 259 
either in controls or in obese patients. Within these two groups, males and females were 260 
matched for age, weight, BMI and distribution of UGT1A1 genotypes (Table 1) and, 261 
therefore, the analysis of TB was not affected by these factors.  262 
In the present manuscript, obese patients and controls were matched for age and 263 
distribution of UGT1A1 genotypes, allowing the comparison of groups. Independently of 264 
gender, obese patients presented higher RBC count, Hb levels and Ht values compared with 265 
controls (Table 1). The higher weight and BMI in obese patients trigger the stimulation of 266 
erythropoiesis in order to supply adequate oxygenation to increased body tissues. However, 267 
TB levels were similar between groups. This may be explained by the fact that obesity is 268 
associated with increased inflammation [16, 36, 37] and oxidative stress [38, 39], and that 269 
bilirubin, presenting antioxidant and anti-inflammatory properties [9, 10], may be somewhat 270 
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consumed. In fact, oxidative stress increases with increasing BMI and age [34]. In line with 271 
this, we found that bilirubin levels are negatively correlated with body and trunk fat 272 
percentages and CRP levels within obese patients. Moreover, when obese patients were 273 
divided in two groups according to the median value of body fat presented by this group 274 
(42.5%), patients presenting higher body fat presented lower bilirubin and higher CRP levels 275 
(Table 2). The negative relation that we found between bilirubin and CRP levels is in line 276 
with the bilirubin's anti-inflammatory activity, as previously reported [40-43].   277 
In obese patients, insulin resistance may also underlie the association between lower 278 
bilirubin levels and higher body fat percentages. Indeed, it seems that the activity of heme 279 
oxygenase-1, the rate-limiting enzyme of bilirubin production, is impaired in insulin resistant 280 
states [44, 45]. Also, the up-regulation of heme oxygenase-1 in adipocyte by insulin was 281 
recently demonstrated [46]. In this work obese patients presented with higher HOMAIR values 282 
compared to controls (Table 1). Obese patients with body fat percentages higher than 42.5% 283 
also presented with higher HOMAIR values, although without statistical significance. 284 
However, no significant correlation was obtained between HOMAIR and bilirubin. Thus, 285 
association between insulin resistance and bilirubin might not be so clear in paediatric 286 
populations. 287 
A previous work from our group demonstrated that BMI z-score is significantly and 288 
independently related to the lipid profile in obese children and adolescent [47]. However, in 289 
the present study BMI z-score was poorly related with TB levels in obese patients and it was 290 
not an independent predictor of bilirubin plasma concentration. This suggests that body fat 291 
percentage is a better indirect marker of oxidative stress, rather than BMI z-score. Actually 292 
BMI z-score is calculated using the BMI of patients, adjusted to age and gender, but it may 293 
not necessarily express the degree of obesity. 294 
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Individuals with a higher physical fitness index (which serves as an aerobic assessment) 295 
seem to present with higher bilirubin levels [24] and a study performed in overweight and 296 
obese adult patients demonstrated an increase in bilirubin levels due to short-term weight loss 297 
[35]. It seems that high doses of exercise training are necessary to significantly increase 298 
bilirubin levels in overweight and obese women [48]. The fact that bilirubin levels increase as 299 
a function of weight loss may be of particular importance in obese individuals with UGT1A1 300 
genotypes associated to lower bilirubin levels, as we here demonstrated effects on TB by 301 
body fat composition in addition to the UGT1A1*28 polymorphism. It is important to keep in 302 
mind that atherosclerosis is a multifactorial disease that initiates early in life, involving the 303 
interplay of genetic and environmental factors. The lifestyle improvement is conditioned by 304 
environmental factors (such as nutritional behaviour and practice of physical activity) and 305 
may be particularly worthy in obese individuals with a less favourable genetic background.   306 
Despite the new data reported here, this work presented some limitations. Obesity was 307 
defined according to CDC although a novel criteria is now recommended for the Portuguese 308 
population, causing us to have probably underestimated the degree of obesity. Nevertheless, 309 
at the beginning of this study the criteria recommend by the Portuguese Ministry of Health 310 
was that of CDC. Also, the evaluation of body composition by DEXA was performed only in 311 
a subgroup of participants due to logistical constraints and equipment availability. 312 
Furthermore, we did not evaluate the association between bilirubin and the MS as a large 313 
proportion of our obese patients were under the age of 10, not allowing their classification 314 
according to the International Diabetes Federation (IDF) definition. 315 
In conclusion, body fat percentage is a major determinant of TB levels independently of 316 
UGT1A1*28 polymorphism in obese children and adolescents. This may have a particular 317 
relevance, as obese individuals, particularly those with 6/6 UGT1A1 genotype and higher 318 
body fat mass, may benefit from a closer clinical follow-up, considering their increased risk 319 
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for other comorbidities. Moreover, lifestyle modifications at low ages, when good habits can 320 
be created, should be highly encouraged in such obese children and adolescents. 321 
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Figure 1. Total bilirubin levels in all participants according to the number of TA 485 
repeats in the promoter region of UGT1A1 gene (A) and also according to group (B), 486 
control and obese. The boxes represent the interquartile range (IQR), with the upper and 487 
lower edges of the boxes representing the 75th and 25th percentiles, respectively. The 488 
central horizontal lines within the boxes represent median levels for each group. The 489 
vertical whiskers above and below the boxes represent the range of outlying data points 490 
up to 1.5 times the IQR.  491 
492 
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Figure 2. Total bilirubin (A) and C-reactive protein (B) levels in obese participants 493 
according to gender and to body fat percentage (n=74), using the cut-off value of 42.5 % 494 
(cut-off that corresponds to the median value for the obese group). The boxes represent 495 
the interquartile range (IQR), with the upper and lower edges of the boxes representing the 496 
75th and 25th percentiles, respectively. The central horizontal lines within the boxes represent 497 
median levels for each group. The vertical whiskers above and below the boxes represent the 498 
range of outlying data points up to 1.5 times the IQR.  499 
500 
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Figure 3. Effect of body fat percentage on total bilirubin levels according to UGT1A1*28 501 
polymorphism on obese patients. For a better visualization of the results we used for body 502 
fat percentage a cut-off of 42.5% (cut-off that corresponds to the median value for the obese 503 
group). Results are presented as mean ± standard error of mean. The influence of body fat 504 
percentage, adjusted for UGT1A1 polymorphism, on total bilirubin levels, was highly 505 
significant (p = 0.009), by multiple regression analysis. 506 
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Table 1. Anthropometric data, UGT1A1*28 polymorphism, haematological and biochemical 507 
parameters of the participants in the study 508 
p p p † p ††
Number of participants 47 32 182 168
Age (years) 10.5 ± 4.0 10.7 ± 3.6 0.830 11.6 ± 2.9 11.7 ± 2.9 0.559 0.083 0.113
Height (cm) 139.7 ± 17.9 143.8 ± 17.6 0.317 151.3 ± 13.2 155.4 ± 15.4 0.008 <0.001 <0.001
Weight (kg) 37.0 ± 14.6 39.7 ± 15.8 0.440 72.1 ± 22.5 76.2 ± 27.4 0.128 <0.001 <0.001
BMI (kg/m²) 18.1 ± 2.9 18.3 ± 2.9 0.691 30.7 ± 5.8 30.5 ± 6.4 0.762 <0.001 <0.001
BMI z-score 0.17 ± 0.65 0.24 ± 0.77 0.636 2.22 ± 0.34 2.30 ± 0.40 0.046 <0.001 <0.001
Body fat (%) 30.8a ± 4.1 25.4b ± 5.2 0.001 43.5c ± 4.1 39.8d ± 6.6 0.156 <0.001 <0.001
Trunk fat (%) 25.6a ± 4.8 21.9b ± 6.0 0.045 41.1c ± 8.9 37.8d ± 7.9 0.107 <0.001 <0.001
UGT1A1
 genotype
6/6, n  (%) 21 (44.7%) 12 (37.5%) 0.298 92 (50.6%) 89 (53.0%) 0.433 0.455 0.085
6/7, n  (%) 21 (44.7%) 19 (59.4%) 79 (43.4%) 64 (38.1%)
7/7, n  (%) 5 (10.6%) 1 (3.1%) 11 (6.0%) 15 (8.9%)
RBC (x1012/L) 4.62 ± 0.29 4.77 ± 0.29 0.031 4.78 ± 0.32 5.03 ± 0.39 <0.001 0.003 <0.001
Hb (g/dL) 13.1 ± 0.9 13.6 ± 1.2 0.029 13.6 ± 0.8 14.2 ± 1.2 <0.001 0.001 0.017
Ht (L/L) 0.39 ± 0.03 0.40 ± 0.04 0.263 0.40 ± 0.02 0.42 ± 0.03 <0.001 0.033 0.003
MCV (fL) 84.9 ± 4.6 84.0 ± 6.1 0.486 84.2 ± 5.1 83.8 ± 4.7 0.454 0.432 0.846
MCH (pg) 28.4 ± 1.7 28.6 ± 2.0 0.684 28.5 ± 1.7 28.2 ± 1.6 0.185 0.909 0.239
MCHC (g/dL) 33.4 ± 1.2 34.0 ± 1.1 0.025 33.8 ± 1.0 33.7 ± 1.1 0.271 0.027 0.081
Total bilirubin (µmol/l) 8.89 (5.47-13.34) 7.52 (5.30-11.54) 0.463 8.89 (6.16-11.63) 9.23 (6.84-12.65) 0.232 0.919 0.079
Acute phase protein
CRP (mg/L) 0.26 (0.20-0.73) 0.36 (0.26-0.83) 0.121 1.83 (0.85-3.73) 1.64 (0.85-3.54) 0.527 <0.001 <0.001
Glucose metabolism
Glucose (mg/dl) 85.3 ± 9.3 87.0 ± 6.5 0.365 84.0 ± 8.9 85.8 ± 12.6 0.121 0.384 0.419
Insulin (µU/ml) 6.8 (5.0-9.9) 5.3 (4.1-8.5) 0.051 16.6 (11.7-23.2) 12.8 (9.1-20.0) 0.001 <0.001 <0.001
HOMAIR 1.41 (1.06-2.05) 1.14 (0.82-1.83) 0.130 3.39 (2.21-4.87) 2.75 (1.88-4.06) 0.006 <0.001 <0.001
Females Males
Obese patients (n =350)Controls (n =79)
Females Males
 509 
Values are given as mean ± SD or median (interquartile range), unless otherwise indicated. 510 
BMI, body mass index; RBC, red blood cells; Hb, haemoglobin; Ht, haematocrit; MCV, mean cell volume; MCH, mean cell haemoglobin; 511 
MCHC, mean cell haemoglobin concentration; CRP, C-reactive protein; HOMAIR, homeostasis model assessment insulin resistance. 512 
a, n=25; b, n=15; c, n=34; d, n=40. 513 
† Controls versus obese patients (females) 514 
†† Controls versus obese patients (males) 515 
 516 
 517 
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Table 2. Anthropometric data, UGT1A1*28 polymorphism, haematological and biochemical 518 
parameters of obese patients according to body fat percentage (n=74) lower or higher/equal 519 
than 42.5% (median value for the obese group) 520 
p
Number of participants 37 37
Female, n  (%) 13 (35.1%) 21 (56.8%) 0.102
Age (years) 11.0 ± 3.0 9.5 ± 2.5 0.022
Height (cm) 149.2 ± 14.3 144.0 ± 14.2 0.126
Weight (kg) 59.8 ± 18.9 61.4 ± 23.9 0.749
BMI (kg/m²) 26.0 ± 4.0 28.4 ± 5.5 0.041
BMI z-score 1.98 ± 0.24 2.31 ± 0.26 <0.001
Body fat (%) 36.8 ± 4.3 46.1 ± 2.6 <0.001
Trunk fat (%) 34.5 ± 5.5 45.3 ± 3.4 <0.001
UGT1A1
 genotype
6/6, n  (%) 21 (56.8%) 19 (51.4%) 0.359
6/7, n  (%) 14 (37.8%) 18 (48.6%)
7/7, n  (%) 2 (5.4%) 0 (0%)
RBC (x1012/L) 4.83 ± 0.38 4.91 ± 0.34 0.389
Hb (g/dL) 13.9 ± 1.0 13.6 ± 0.8 0.268
Ht (L/L) 0.41 ± 0.03 0.41 ± 0.02 0.798
MCV (fL) 85.4 ± 4.9 83.8 ± 4.6 0.156
MCH (pg) 28.7 ± 1.7 27.8 ± 1.5 0.017
MCHC (g/dL) 33.6 ± 0.8 33.2 ± 0.9 0.020
Total bilirubin (µmol/l) 11.29 (8.72-14.36) 8.89 (7.69-11.63) 0.013
Acute phase protein
CRP (mg/L) 1.31 (0.84-2.30) 2.00 (1.43-3.54) 0.017
Glucose metabolism
Glucose (mg/dl) 83.5 ± 7.6 81.0 ± 8.6 0.191
Insulin (µU/ml) 11.6 (8.9-14.6) 15.3 (7.5-22.9) 0.272
HOMAIR 2.25 (1.91-3.01) 3.15 (1.57-4.56) 0.361
Body fat ≤ 42.5% Body fat > 42.5%
Obese patients (n =74)
 521 
Values are given as mean ± SD or median (interquartile range), unless otherwise indicated. 522 
BMI, body mass index; RBC, red blood cells; Hb, haemoglobin; Ht, haematocrit; MCV, mean cell volume; MCH, mean cell haemoglobin; 523 
MCHC, mean cell haemoglobin concentration; CRP, C-reactive protein; HOMAIR, homeostasis model assessment insulin resistance. 524 
Fig. 1
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